Condition
Recurrent Inflammatory Breast Carcinoma
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
3 of 0 completed with results
Key Signals
3 with results0
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Terminated2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02411656Phase 2Active Not Recruiting
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
NCT02658812Phase 2Terminated
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
NCT02892734Phase 2Terminated
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Showing all 3 trials